Jonathan P. Foster - 12 Nov 2025 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Reporting relationship: EVP & CFO
Issuer ticker: MBRX
Reported as of: 12 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Nov 2025, 16:08:22 UTC
Prior SEC filing: 06 Nov 2025
Next SEC filing: 20 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan P. Foster

Key filing fact

Jonathan P. Foster filed Form 4 for Moleculin Biotech, Inc. (MBRX) on 14 Nov 2025.

Key facts

This page summarizes Jonathan P. Foster's Form 4 filing for Moleculin Biotech, Inc. (MBRX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Nov 2025, 16:08.

Change

Previous filing in this sequence was filed on 06 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001545414 Primary reporting owner

Foster Jonathan P.

Relationship: EVP & CFO
Address: C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON
Signature: /s/ Jonathan P. Foster
Signature date: 14 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MBRX transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares: +600,000
Change %: +59%
Price
Shares after: 1,617,695
Date: 12 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 600,000
Exercise price: $0.4900
Footnotes: F1, F2

MBRX transaction Derivative

Performance Based Restricted Stock Units

Award

Transaction value
Shares: +400,000
Change %: +25%
Price
Shares after: 2,017,695
Date: 12 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.

Footnote F2

Issued in connection with the reporting person's employment with the Company.

Footnote F3

Each restricted stock unit represents a contingent right to receive one shares of Company common stock.

Footnote F4

On November 12, 2025, the Board approved this performance based restricted stock unit. The performance based restricted stock units set forth in this table will vest in 20% installments upon the achievement of certain clinical milestones; provided that upon a change of control (as defined in the 2024 Stock Plan) 100% shall vest.